CLEC1B and neoplasm: Tsai et al. 2024, [122] employed SELEX to select aptamers which specifically bind to the Podoplanin protein (present on the surface of various tumor cells), in order to prevent its interaction with the platelet receptor CLEC-2, to block tumor platelet aggregation and reduce the tumor cells’ metastatic potential.